Investors should review the proxy statement before voting, particularly regarding the equity incentive plan amendment which could impact share count. The opposition to shareholder proposals suggests management maintains a firm stance on governance and ESG reporting policies.
Price Chart
Executive Summary
Gilead Sciences is holding its 2026 Annual Meeting, where shareholders will vote on several key proposals. The board recommends voting in favor of re-electing all nine director nominees, ratifying Ernst & Young as auditors, approving executive compensation, and amending the equity incentive plan. The board opposes three shareholder proposals requesting an independent board chair, a report on patent exclusivity impacts on patient access, and a report on ESG/DEI compensation metrics.
Key Facts
- Annual shareholder meeting scheduled for April 30, 2026
- Nine director nominees up for re-election, including Daniel P. O'Day and Kelly A. Kramer
- Board recommends ratification of Ernst & Young as independent auditors
- Board recommends approval of amended 2022 Equity Incentive Plan
- Board opposes three shareholder proposals on governance and ESG reporting
- Shareholders can vote on executive compensation (advisory vote)
Financial Impact
No immediate financial impact from the proxy vote itself, but the equity incentive plan amendment could affect future share dilution
Risk Factors
- Potential shareholder dissatisfaction with board opposition to governance and ESG proposals
- Future dilution from the amended equity incentive plan
- Executive compensation decisions could impact investor sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001308179-26-000107 |
| Document: 0001308179-26-000107-index-headers.html | 0001308179-26-000107 |
| Document: 0001308179-26-000107-index.html | 0001308179-26-000107 |
| Document: 0001308179-26-000107.txt | 0001308179-26-000107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $149.61 $149.05 | ▼ −0.37% | ▼ −0.04% | $144.74 (−3.26%) |
Aug 27, 2026 5w ago | Insider Cluster | $145.68 $152.21 | ▲ +4.48% | ▲ +4.22% | $144.74 (−0.65%) |
Aug 21, 2026 5w ago | Insider Cluster | $146.74 $152.67 | ▲ +4.04% | ▲ +2.73% | $144.74 (−1.36%) |
Aug 18, 2026 6w ago | Insider Cluster | $147.60 $150.89 | ▲ +2.23% | ▲ +4.18% | $144.74 (−1.94%) |
Aug 18, 2026 6w ago | Court Ruling | $143.44 $147.68 | ▲ +2.96% | ▲ +4.27% | $144.74 (+0.91%) |
Aug 13, 2026 7w ago | Court Ruling | $138.14 $143.72 | ▲ +4.04% | ▲ +5.79% | $144.74 (+4.78%) |
Aug 6, 2026 8w ago | S-3ASR | $133.21 $151.00 | ▲ +13.35% | ▲ +13.75% | $144.74 (+8.66%) |
Jul 21, 2026 10w ago | ANALYST-DOWNGRADE | $130.28 $143.44 | ▼ −10.10% | ▼ −7.54% | $144.74 (−11.10%) |
Jul 16, 2026 11w ago | Insider Cluster | $134.28 $138.33 | ▲ +3.02% | ▼ −1.43% | $144.74 (+7.79%) |
Jul 6, 2026 12w ago | ANALYST-UPGRADE | $129.61 $130.21 | ▲ +0.46% | ▲ +1.03% | $144.74 (+11.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access